Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial

2021 ◽  
Author(s):  
Jonathan D. Schoenfeld ◽  
Anita Giobbie-Hurder ◽  
Srinika Ranasinghe ◽  
Katrina Z. Kao ◽  
Ana Lako ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Low Dose ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Targeted Radiotherapy ◽  
Phase 2 Trial ◽  
Randomized Phase 2

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

2020 ◽  
Vol 21 (6) ◽  
pp. 786-795 ◽  
Author(s):  
Catherine A Shu ◽  
Justin F Gainor ◽  
Mark M Awad ◽  
Codruta Chiuzan ◽  
Claud M Grigg ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial

scholarly journals Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

Cancer ◽  
2015 ◽  
Vol 121 (18) ◽  
pp. 3298-3306 ◽  
Author(s):  
Karen L. Reckamp ◽  
Marianna Koczywas ◽  
Mihaela C. Cristea ◽  
Jonathan E. Dowell ◽  
He-Jing Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Dose ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Trial ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document